GSKGSK.NValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, GSK (GSK.N) trades at a P/E of 15.70x, P/B of 4.29x, P/S of 2.27x, and a dividend yield of 2.78%.
Longitudinal percentile comparison: P/E sits at the 42nd percentile over the trailing 10Y window (vs. 48th percentile over 3Y); P/B sits at the 12th percentile over the trailing 10Y window (vs. 27th percentile over 3Y); P/S sits at the 47th percentile over the trailing 10Y window (vs. 69th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 27th percentile within its industry and the 40th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.63%, ranking at the 30th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 30.1 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Of the 4.63% total shareholder yield, 2.78% is paid out as dividends and roughly 1.85% is implied to come from buybacks — both channels are meaningfully in play. GSK operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NYSE: GSK · GSK
Want the full picture on whether GSK (GSK.N) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 15.70 | ||||||
| P/B (MRQ) | 4.29 | ||||||
| P/S (TTM) | 2.27 | ||||||
| Dividend Yield | 2.78% | ||||||
| Buyback + Div Yield | 4.63% |